Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 12/20 | 0.53 |
| ▸ | HTR2C | P28335 | 12/20 | 0.53 |
| ▸ | HTR2B | P41595 | 12/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.53 |
| ▸ | HTR1A | P08908 | 2/20 | 0.49 |
| ▸ | HTR7 | P34969 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31808827 | 1.00 | DRD3 (0.54) | DRD3HTR2AHTR2CHTR2BHRH3 | |
| Hydrochloric Acid SCHEMBL10462146 | 0.91 | SIGMAR1 (0.50) | DRD3HTR2AHTR2CHTR2BHRH3 | |
| SCHEMBL823058 | 0.84 | HTR1A (0.61) | DRD3HTR1AHTR7 | |
| SCHEMBL29507805 | 0.84 | HTR1A (0.61) | DRD3HTR1AHTR7 | |
| SCHEMBL1950024 | 0.84 | HTR1A (0.61) | DRD3HTR1AHTR7 | |
| SCHEMBL822940 | 0.84 | HTR1A (0.61) | DRD3HTR1AHTR7 | |
| SCHEMBL7092682 | 0.84 | DRD3 (0.54) | DRD3HTR2AHTR2CHTR2BHRH3 | |
| Hydrochloric Acid SCHEMBL29064497 | 0.83 | HTR1A (0.59) | DRD3HTR1AHTR7 | |
| SCHEMBL10463903 | 0.83 | MAOA (0.50) | HTR2AHTR2CHTR2BHRH3SIGMAR1 | |
| SCHEMBL10462534 | 0.83 | BRD4 (0.49) | HTR2AHTR2CHTR2BHRH3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1924553-A1 | BICYCLO[2.2.]HEPT-7-YLAMINE DERIVATIVES AND THEIR USES | Argenta Discovery Limited (GB) | 2008-05-28 | — | — | EP | claimed |
| WO-2007017670-A1 | BICYCLO[2.2.]HEPT-7-YLAMINE DERIVATIVES AND THEIR USES | ARGENTA DISCOVERY LTD. (GB) | 2007-02-15 | — | — | WO | claimed |
| CN-118221656-A | Compounds useful for the treatment of gastrointestinal disorders | 阿德利克斯股份有限公司 | 2024-06-21 | — | — | CN | disclosed |
| CN-114315796-B | Compounds used as HPK1 kinase inhibitor, preparation method and application thereof | 中国药科大学 | 2024-03-26 | — | — | CN | disclosed |
| CN-110267944-B | Compounds useful for the treatment of gastrointestinal disorders | 阿德利克斯股份有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-114315796-A | Compound used as HPK1 kinase inhibitor and preparation method and application thereof | 中国药科大学 | 2022-04-12 | — | — | CN | disclosed |
| EP-2887964-B1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX INC (US) | 2019-07-03 | — | — | EP | disclosed |
| US-7989451-B2 | Tricyclic 1,2,4-triazine oxides and compositions for therapeutic use in cancer treatments | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-08-02 | — | — | US | disclosed |
| US-7989451-B2 | Tricyclic 1,2,4-triazine oxides and compositions for therapeutic use in cancer treatments | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-08-02 | — | — | US | disclosed |
| US-7989451-B2 | Tricyclic 1,2,4-triazine oxides and compositions for therapeutic use in cancer treatments | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-08-02 | — | — | US | disclosed |
| CN-102056894-A | Homocysteine synthase inhibitor | MITSUBISHI TANABE PHARMA CORP | 2011-05-11 | — | — | CN | disclosed |
| EP-1866292-B1 | TRICYCLIC 1,2,4-TRIAZINE OXIDES AND COMPOSITIONS THEREFROM FOR THERAPEUTIC USE IN CANCER TREATMENTS | AUCKLAND UNISERVICES LTD (NZ) | 2010-12-15 | — | — | EP | disclosed |
| EP-2261218-A2 | Process for preparing phenyl-, pyridinyl- or pyrimidinyl-substituted imidazoles | Eisai R&D Management Co., Ltd. (JP) | 2010-12-15 | — | — | EP | disclosed |
| US-20090186886-A1 | Tricyclic 1,2,4-Triazine Oxides and Compositions for Therapeutic Use in Cancer Treatments | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-07-23 | — | — | US | disclosed |
| US-20090186886-A1 | Tricyclic 1,2,4-Triazine Oxides and Compositions for Therapeutic Use in Cancer Treatments | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-07-23 | — | — | US | disclosed |
| US-20090186886-A1 | Tricyclic 1,2,4-Triazine Oxides and Compositions for Therapeutic Use in Cancer Treatments | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-07-23 | — | — | US | disclosed |
| EP-1757591-A1 | CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186886-A1 | Tricyclic 1,2,4-Triazine Oxides and Compositions for Therapeutic Use in Cancer Treatments | HIF1AN, HIF1A, HYOU1 | DRD3 3070/4885HTR2A 269/4885HTR2C 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.